Immunomodulation of E.Coli Nissle 1917 in Patients With Grass Pollen Rhinoconjunctivitis

• Status: Completed
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Due to the worldwide increasing prevalence of the allergic rhinoconjunctivitis, new therapeutical strategies are needed. The symptomatic treatment with topical and systemic antihistamines and corticosteroids are often insufficient. E.coli Nissle 1917 has immunomodulatory capacities and reveals less side effects. E.coli Nissle 1917 has no sedative properties and exhibits no hepatotoxic qualities. Thus, E.coli Nissle 1917 represents a new relevant therapeutical agent.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Charite University, Berlin, Germany

Criteria

Inclusion Criteria:

• clinical relevant grass pollen allergy with required treatment since 2 years

• positive skin prick test to grass

• positive sIgE towards grass (CAP 2)

• written informed consent

Exclusion Criteria:

• perennial rhinoconjunctivitis

• sinusitis

• chronic diarrhoea and other existing severe gastrointestinal diseases

• current specific immunotherapy to grass pollen